Latest:

Fat Pitch Financials

Special situation stocks and value investing

Stock Quote

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sage Therapeutic Com (NQ: SAGE )

43.27 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 15, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 43.27
Bid (Size) 20.95 (1)
Ask (Size) 44.81 (2)
Prev. Close 43.27
Today's Range 43.27 - 43.27
52wk Range 27.36 - 47.75
Shares Outstanding 59,422,343
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Covid Exposed A 'Brain Health Pandemic' — Here's How Biotech Stocks Like Biogen, Sage Therapeutics Could Help
Today's depression drugs don't fit many patients' needs. Biotech companies may change that. 
Via Investor's Business Daily
Biotech Daily: Trial Setback For Eliem Therapeutics, Allarity Drops Work On Cancer Monotherapies, Axcella Aces Long COVID Study
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga

Performance

YTD
-0.73%
-0.73%
1 Month
+26.59%
+26.59%
3 Month
+34.30%
+34.30%
6 Month
+2.32%
+2.32%
1 Year
+1.93%
+1.93%

More News

Read More
Sage Therapeutics: Q2 Earnings Insights
Via Benzinga
Sage Therapeutics Announces Second Quarter 2022 Financial Results and Highlights Pipeline and Business Progress
From Sage Therapeutics, Inc.
Via Business Wire
Where Sage Therapeutics Stands With Analysts
Via Benzinga
8 Analysts Have This to Say About Sage Therapeutics
Via Benzinga
Sage Therapeutics: Q1 Earnings Insights
Via Benzinga
Earnings Scheduled For August 2, 2022
Via Benzinga
Sage Therapeutics to Present at Upcoming August Investor Conferences
From Sage Therapeutics, Inc.
Via Business Wire
Sage Therapeutics to Report Second Quarter 2022 Financial Results on Tuesday, August 2, 2022
From Sage Therapeutics, Inc.
Via Business Wire
R&D Efforts for Central Nervous System (CNS) Therapeutics Have Resulted in Hopeful Novel Drug-Delivery Solutions
Via FinancialNewsMedia
Sage Therapeutics to Present at Upcoming June Investor Conferences
From Sage Therapeutics, Inc.
Via Business Wire
Sage Therapeutics And Biogen Tackle Depression — And Their Stocks Do The Same
Via Investor's Business Daily
Sage Therapeutics and Biogen Announce that the Phase 3 SKYLARK Study of Zuranolone in Postpartum Depression Met its Primary and All Key Secondary Endpoints
From Sage Therapeutics, Inc.
Via Business Wire
Analyst Ratings for Sage Therapeutics
Via Benzinga
Sage Therapeutics to Present at Bank of America Securities 2022 Healthcare Conference
From Sage Therapeutics, Inc.
Via Business Wire
The Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme Layoffs
Via Benzinga
Sage Therapeutics Announces First Quarter 2022 Financial Results and Highlights Pipeline and Business Progress
From Sage Therapeutics, Inc.
Via Business Wire
Earnings Scheduled For May 3, 2022
Via Benzinga
Sage Therapeutics, Biogen Start Rolling Submission For Zuranolone In Major Depressive Disorder
Via Benzinga
The Week Ahead In Biotech (May 1-7): Phathom FDA Decision, Pfizer, Vertex Pharma Lead Earnings News, Ophthalmology Conference Presentations, And More
Via Benzinga
Sage Therapeutics and Biogen Initiate Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration for Zuranolone for the Potential Treatment of Major Depressive Disorder (MDD)
From Sage Therapeutics, Inc.
Via Business Wire
Sage Therapeutics Earnings Conference Call Is Coming Up, Here's What You Need To Know
Via Benzinga
Sage Therapeutics to Report First Quarter 2022 Financial Results on Tuesday, May 3, 2022
From Sage Therapeutics, Inc.
Via Business Wire
The Daily Biotech Pulse: Thervance Gains On Positive Late-Stage Readout, Bristol-Myers Squibb Snags 3 Approvals In Europe, Decision Day For BioXcel
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.